Final Results of the HERACLES trial in HER2 amplified colorectal cancer

Authors:
  • SSS. Siena
    S. Siena
  • ASA. Sartore-Bianchi
    A. Sartore-Bianchi
  • LTL. Trusolino
    L. Trusolino
  • CMC. Martino
    C. Martino
  • KBK. Bencardino
    K. Bencardino
  • SLS. Lonardi
    S. Lonardi
  • VZV. Zagonel
    V. Zagonel
  • FLF. Leone
    F. Leone
  • EME. Martinelli
    E. Martinelli
  • FCF. Ciardiello
    F. Ciardiello
  • PRP. Racca
    P. Racca
  • AAA. Amatu
    A. Amatu

Abstract
Background: HER2 amplification is found in 5% of RAS wild type (RASWT) metastatic colorectal cancer (mCRC). Dual HER2 blockade with trastuzumab (T) and lapatinib (L), but not treatment with either drug alone, led to remarkable inhibition of tumour growth in patient-derived tumourgrafts of HER2-amplified mCRC. CRC-specific criteria for HER2 positivity by immunohistochemistry (IHC) and in situ hybridization (ISH) were defined retrospectively in 256 CRC paraffin embedded samples (HERACLES DGX criteria). The ensuing diagnostic algorithm was utilised to screen 1081 HER2-positive tumours for therapeutic targeting in patients in the HERACLES phase 2 trial.